COVID-19–directed therapy and anticoagulation were considered based on disease severity as part of the recommended supportive care.23,25 Coagulopathy is a known adverse effect of asparaginase, adding to the risk of thrombosis from COVID-19, as seen in 2 of the patients in this study. This evidence concerns the gene ASPG and COVID-19.